Provepharm - Back to HomepageMethylene Blue
The first pure pharma grade Methylene Blue produced under cGMP in the World
Product
General Information
Drug Substance
Typical Analysis
Applications
Human Health
Animal Health
Other Applications
Documentation
Request Documentation
Download General Brochure
Useful Links
News
Contacts
Provepharm
Inquiry

Human Health


Currently approved therapeutic indications and dose forms

Methemoglobinemia
First-line antidote agent for methemoglobinemia.
Methemoglobinemia occurs when the blood cannot deliver oxygen where it is needed in the body (because of cyanide poisoning for example).
  • WHO Model Lists of Essential Medicines1
  • Orphan drug for : Hereditary methemoglobinemia, recessive2
  • Injectable: 1% & 5%
Antiseptic
Mild urinary antiseptic (cystitis treatment)
  • Tablet: 50 mg & 65 mg
Ocular disinfectant
  • Blue eyes drop: 0,1%
Topical Antiseptic
  • Solutions, Lotion: 1% & 2%

New applications under investigation

Antiviral
  • HCV and HIV
Anti-parasitic
  • Malaria (alone and in combination)
Cognitive dysfunction
  • Alzheimer’s disease and other cognitive dysfunction3

Selected non-clinical data


Clinical trials4

The web site http://clinicaltrials.gov is a registry of US federally and privately supported clinical trials conducted in the United States and around the world.
11 studies in progress are listed as at 10 january 2008 concerning methylene blue.

Methylene Blue Chromoendoscopy in Barrett's Esophagus
Condition: Barrett Esophagus

Methylene Blue for Cognitive Dysfunction in Bipolar Disorder
Trial Phase III
Condition: Bipolar Disorder

Studies of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome
Trial Phase I
Condition: Sepsis

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
Condition: Cervical Cancer

BlueCQ (Methylene Blue; Chloroquine) Bioavailability
Trial Phase I

Interaction Between Anaesthetics and Methylene Blue
Condition: Hyperparathyroidism

Plasma Transfusion in Liver Transplantation
Trial Phase IV
Condition: Bleeding in Liver Transplantation

Safety and Efficacy of Methylene Blue Combined With Artesunate
or Amodiaquine for Malaria Treatment in Children of Burkina Faso:
a Pilot Study
Trial Phase II
Condition: Malaria

Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope
Condition: Infiltrative Breast Cancer

Methylene Blue in Sepsis: A Randomized Controlled Trial
Condition: Sepsis

Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso
Trial Phase II
Condition: Malaria
1 15th list, March 2007 (page 3) www.who.int/medicines/publications/EML15.pdf
2 www.orpha.net/data/patho/FR/fr-mhr.pdf
3 F. Gonzalez-Lima and Aleksandra K. Bruchey; Methylene Blue Extinction Memory Improvement by the Metabolic Enhancer ; Institute for Neuroscience and Departments of Psychology, Pharmacology and Toxicology, University of Texas at Austin, USA
4 http://clinicaltrials.gov/ct2/results?term=methylene+blue
© Provepharm 2007 - WebDesign: Landscape